Fig. S6.


ECLC26 lung cancer
MDA-MB-231 breast cancer
PC-3 prostate cancer
a
b
c
Doxorubicin
Dox-C' dot
Viability
(% of Untreated Control)
Concentration
(uM)
LD50
1295 nM
LD50
4.4 nM
LD50
127 nM
LD50
3.9 nM
LD50
434.6 nM
LD50
8.47 nM
Rcas cells uptake
RCAS/tv-a glioma cells
d
e
Vehicle
DOX (250 nM)
Dox-C' dots (250 nM)
Proliferation Index
Incubation time (h)
Median fluorescence intensity (Cy5)
0 nM
10 nM
50 nM
125 nM
250 nM